Saltar al contenido
Merck

Mitogen-Inducible Gene 6 Inhibits Angiogenesis by Binding to SHC1 and Suppressing Its Phosphorylation.

Frontiers in cell and developmental biology (2021-03-12)
Lixian Liu, Liying Xing, Rongyuan Chen, Jianing Zhang, Yuye Huang, Lijuan Huang, Bingbing Xie, Xiangrong Ren, Shasha Wang, Haiqing Kuang, Xianchai Lin, Anil Kumar, Jong Kyong Kim, Chunsik Lee, Xuri Li
RESUMEN

The mitogen-inducible gene 6 (MIG6) is an adaptor protein widely expressed in vascular endothelial cells. However, it remains unknown thus far whether it plays a role in angiogenesis. Here, using comprehensive in vitro and in vivo model systems, we unveil a potent anti-angiogenic effect of MIG6 in retinal development and neovascularization and the underlying molecular and cellular mechanisms. Loss of function assays using genetic deletion of Mig6 or siRNA knockdown increased angiogenesis in vivo and in vitro, while MIG6 overexpression suppressed pathological angiogenesis. Moreover, we identified the cellular target of MIG6 by revealing its direct inhibitory effect on vascular endothelial cells (ECs). Mechanistically, we found that the anti-angiogenic effect of MIG6 is fulfilled by binding to SHC1 and inhibiting its phosphorylation. Indeed, SHC1 knockdown markedly diminished the effect of MIG6 on ECs. Thus, our findings show that MIG6 is a potent endogenous inhibitor of angiogenesis that may have therapeutic value in anti-angiogenic therapy.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Methyl cellulose, viscosity: 4,000 cP
Sigma-Aldrich
Anti-β-actina monoclonal antibody produced in mouse, clone AC-74, ascites fluid
Sigma-Aldrich
Escort III Transfection Reagent, Lipid reagent for transfecting sensitive and primary cells